Skip to Content
Stock Strategist Industry Reports

Implementation of Trump's Drug-Pricing Orders Unlikely

We don't foresee any impact on pharma companies' moats or valuations.

Mentioned: , , , , , , , , ,

President Donald Trump issued several orders on Nov. 20 designed to lower U.S. drug prices. We don’t expect implementation of these orders, however, given legal challenges, lack of support from the U.S. Congress and the incoming Biden administration, and unclear financial impacts. As a result, we don’t expect any major impact on the U.S. pricing power of drugs, a core pillar of our economic moat ratings and valuations in the drug industry.

One of the White House directives focused on pricing 50 of the largest Medicare B (hospital-administered) drugs at the lowest levels paid by developed countries. This would significantly affect U.S. prices, as we estimate drug pricing in the United States is close to double the prices in developed markets. However, we expect valid industry legal challenges to stop this order. The order doesn’t appear to have followed the normal legal process and instead was rushed out so Trump could enact the policy before leaving office. Additionally, we believe the rule is difficult to implement without legislative support from Congress. Further, we don’t expect the Biden administration to focus initially on U.S. drug pricing, especially in the form of these recent proposals, which lack full legal and congressional support.

Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.